BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Jiang Z, Huang Y, Zhang P, Han C, Lu Y, Mo Z, Zhang Z, Li X, Zhao S, Cai F, Huang L, Chen C, Shi Z, Zhang Y, Ling F. Characterization of a pathogenic variant in GBA for Parkinson's disease with mild cognitive impairment patients. Mol Brain 2020;13:102. [PMID: 32641146 DOI: 10.1186/s13041-020-00637-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Rahman MU, Bilal M, Shah JA, Kaushik A, Teissedre PL, Kujawska M. CRISPR-Cas9-Based Technology and Its Relevance to Gene Editing in Parkinson's Disease. Pharmaceutics 2022;14:1252. [PMID: 35745824 DOI: 10.3390/pharmaceutics14061252] [Reference Citation Analysis]
2 Teng MS, Wu S, Hsu LA, Chou HH, Ko YL. Pleiotropic Effects of Functional MUC1 Variants on Cardiometabolic, Renal, and Hematological Traits in the Taiwanese Population. Int J Mol Sci 2021;22:10641. [PMID: 34638981 DOI: 10.3390/ijms221910641] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
3 Aarsland D, Batzu L, Halliday GM, Geurtsen GJ, Ballard C, Ray Chaudhuri K, Weintraub D. Parkinson disease-associated cognitive impairment. Nat Rev Dis Primers 2021;7:47. [PMID: 34210995 DOI: 10.1038/s41572-021-00280-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 51] [Article Influence: 1.0] [Reference Citation Analysis]
4 Degtyareva AO, Antontseva EV, Merkulova TI. Regulatory SNPs: Altered Transcription Factor Binding Sites Implicated in Complex Traits and Diseases. Int J Mol Sci 2021;22:6454. [PMID: 34208629 DOI: 10.3390/ijms22126454] [Cited by in F6Publishing: 8] [Reference Citation Analysis]
5 Zhu X, Zhang Y, Yang X, Hao C, Duan H. Gene Therapy for Neurodegenerative Disease: Clinical Potential and Directions. Front Mol Neurosci 2021;14:618171. [PMID: 34194298 DOI: 10.3389/fnmol.2021.618171] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
6 Behl T, Kaur G, Fratila O, Buhas C, Judea-Pusta CT, Negrut N, Bustea C, Bungau S. Cross-talks among GBA mutations, glucocerebrosidase, and α-synuclein in GBA-associated Parkinson's disease and their targeted therapeutic approaches: a comprehensive review. Transl Neurodegener 2021;10:4. [PMID: 33446243 DOI: 10.1186/s40035-020-00226-x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 19] [Article Influence: 16.0] [Reference Citation Analysis]
7 Behl T, Kaur G, Fratila O, Buhas C, Judea-pusta CT, Negrut N, Bustea C, Bungau S. Cross-talks among GBA mutations, glucocerebrosidase, and α-synuclein in GBA-associated Parkinson’s disease and their targeted therapeutic approaches: a comprehensive review. Transl Neurodegener 2021;10. [DOI: 10.1186/s40035-020-00226-x] [Reference Citation Analysis]
8 Angelopoulou E, Paudel YN, Villa C, Piperi C. Arylsulfatase A (ASA) in Parkinson's Disease: From Pathogenesis to Biomarker Potential. Brain Sci 2020;10:E713. [PMID: 33036336 DOI: 10.3390/brainsci10100713] [Cited by in F6Publishing: 3] [Reference Citation Analysis]